<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and pathology of miliary and extrapulmonary tuberculosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and pathology of miliary and extrapulmonary tuberculosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and pathology of miliary and extrapulmonary tuberculosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            C Fordham von Reyn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Miliary tuberculosis (TB) refers to clinical disease resulting from the hematogenous dissemination of
         <em>
          Mycobacterium tuberculosis
         </em>
         . The term "miliary" was coined in 1700 by John Jacobus Manget, who likened the appearance of the involved lung with its surface covered with firm small white nodules to numerous millet seeds  (
         <a class="graphic graphic_picture graphicRef76174" href="/z/d/graphic/76174.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         Miliary TB can arise as a result of progressive primary infection or via reactivation of a contained, infected focus with subsequent spread. The term miliary TB was originally a pathologic and then a radiographic description; it is now used more broadly (and incorrectly) by some to denote all forms of progressive, widely disseminated TB, whether or not disease presents with the classic radiographic or pathologic nodular appearance characteristic of hematogenous spread.
        </p>
        <p>
         Tuberculosis may be classified according to site of disease as pulmonary or extrapulmonary; miliary disease has been classified as both an extrapulmonary and a pulmonary form of TB.
        </p>
        <p>
         The epidemiology and pathology of miliary TB will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of miliary TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H299497599">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         TB terminology is inconsistent in the literature and in practice as discussed above [
         <a href="#rid1">
          1
         </a>
         ]. Relevant terms are defined in the table  (
         <a class="graphic graphic_table graphicRef132526" href="/z/d/graphic/132526.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H7622732">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology of miliary TB has been altered by use of chemotherapy for treatment of malignancy, use of biologic agents, the HIV epidemic, and immigration patterns. For reporting purposes, cases with both pulmonary and extrapulmonary disease are classified as pulmonary TB by the United States Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Of 8331 TB cases reported in the United States in 2022, extrapulmonary TB (with no demonstrated pulmonary involvement) accounted for approximately 19 percent of cases. Disease with both pulmonary and extrapulmonary involvement was reported in 10.6 percent of cases [
         <a href="#rid4">
          4
         </a>
         ]. Relative numbers are essentially unchanged since 2021, despite possible associations with COVID-19 and a 5.9 percent increase in the total number of reported cases of TB in the United States in 2022 versus 2021.
        </p>
        <p>
         Generally, fewer than 2 percent of cases demonstrate miliary disease [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Worldwide, estimates of incidence are hampered by incomplete reporting and imprecise diagnostic criteria [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The epidemiology of miliary disease varies between case series:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to the availability of antituberculous therapy, 20 percent of TB autopsy cases at Boston City Hospital had evidence of miliary disease [
         <a href="#rid7">
          7
         </a>
         ]. By the 1970s, with the availability of antituberculous therapy, the incidence had fallen to 0.7 percent [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from the CDC in the early 1980s (after the availability of antituberculous therapy but prior to the HIV epidemic) reported 1.3 percent of TB cases had evidence of miliary disease [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the midst of the HIV epidemic during the mid-1980s, the percentage of miliary TB was higher among HIV-infected patients than HIV-uninfected patients (38 versus 8 percent) [
         <a href="#rid10">
          10,11
         </a>
         ]. Risk for developing miliary TB appeared to be highest among patients with the lowest CD4 counts [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a public health clinic in Ireland in the 1990s, miliary disease accounted for 4 percent of TB cases [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Use of biologic agents such as tumor necrosis factor (TNF)-alpha inhibitors has been associated with a disproportionate increase in cases of extrapulmonary and miliary tuberculosis among individuals treated with these agents. In one study including 70 patients who developed tuberculosis in association with
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         therapy, extrapulmonary disease was observed in 57 percent of cases, and "disseminated" disease was observed in 24 percent of cases [
         <a href="#rid14">
          14
         </a>
         ]. In another study including 40 patients who developed TB in association with anti-TNF-alpha agents (
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , infliximab, or
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ), extrapulmonary TB (including miliary TB) was observed in 62 percent of cases [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The HIV epidemic has played a significant role in increasing the prevalence of miliary TB. Between 1999 and 2006 in England and Wales, an almost fivefold increase in the number of miliary cases was observed (38 to 180 cases); HIV coinfection was most strongly associated with miliary disease [
         <a href="#rid16">
          16
         </a>
         ]. Other factors, such as the emergence of drug-resistant or multidrug-resistant strains, have also contributed [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         While the early COVID-19 pandemic was associated with a decrease in the number of reported cases in the United States in 2020 and 2021, the relative number of extrapulmonary cases has not changed as case numbers appear to be rebounding [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7622739">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for the development of miliary TB include age and underlying medical conditions, especially HIV infection and other immunosuppression. However, a significant percentage of cases described in the literature have no demonstrable high-risk condition for dissemination; miliary TB should never be excluded as a clinical diagnosis because an underlying medical illness is absent.
        </p>
        <p class="headingAnchor" id="H7622746">
         <span class="h3">
          Age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants and young children are highly susceptible to miliary TB, presumably due to their relatively immature immune systems [
         <a href="#rid18">
          18-22
         </a>
         ]. In a study from Puerto Rico, miliary disease or meningitis occurred more frequently among children &lt;6 years than among children &gt;7 years of age (1 versus 0.4 percent, respectively) [
         <a href="#rid19">
          19
         </a>
         ]. In another series from South Africa, miliary TB accounted for more hospital admissions among children than adults (8 versus 1 percent); 52 percent of cases occurred in children &lt;1 year of age [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Miliary TB has been described more frequently among older adults in the post-antibiotic era than the pre-antibiotic era; this group is likely at increased risk due to relative waning of cellular immunity [
         <a href="#rid8">
          8
         </a>
         ]. In addition, the rise of HIV has led to increased prevalence of miliary TB among young adults [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7622753">
         <span class="h3">
          Medical conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The percentage of patients with miliary TB and some identifiable underlying medical condition in various studies ranged from 38 to 70 percent. The most common conditions include [
         <a href="#rid24">
          24-30
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol abuse
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corticosteroids or other iatrogenic immunosuppression (eg, TNF-alpha–blocking agents)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Connective tissue disease (with or without iatrogenic immunosuppression)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy
        </p>
        <p>
        </p>
        <p>
         Weight loss and/or malnutrition are important components of a number of these conditions but have not been addressed separately [
         <a href="#rid24">
          24-28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7622760">
         <span class="h3">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Men outnumber women in most series of miliary TB  (
         <a class="graphic graphic_table graphicRef77719" href="/z/d/graphic/77719.html" rel="external">
          table 2
         </a>
         ); it is uncertain whether this reflects a greater prevalence of TB among men. It is also uncertain whether African-Americans are more likely to progress from infection to disseminated disease, since control for the relative contributions of socioeconomic factors, such as living conditions, nutrition, access to care, and comorbidities, is needed for proper data interpretation [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H7623073">
         <span class="h2">
          Mechanisms of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Miliary or extrapulmonary TB can arise as a result of progressive primary infection or via reactivation of a contained (formerly termed latent) focus with subsequent lymphohematogenous spread. Rarely, iatrogenic infection can occur.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Progressive primary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         After establishing a primary focus of infection in the lung, bacilli can disseminate via the lymphatics and hematogenously  (
         <a class="graphic graphic_algorithm graphicRef66301" href="/z/d/graphic/66301.html" rel="external">
          algorithm 1
         </a>
         ). There is a predilection for spread to the most vascular organs, such as the liver, spleen, bone marrow, and brain. These distant foci usually heal by granulomatous containment over weeks to months as adaptive immunity develops; however, individual lesions harbor viable organisms. Failure of these foci to heal early during primary infection leads to progressive primary disease at these sites. Many adults with progressive TB have underlying medical or iatrogenic conditions that impair the development of effective cell-mediated immunity intended to contain the primary infection.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Reactivation of a viable focus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Miliary TB may result from reactivation of a contained focus of infection with subsequent erosion into adjoining lymphatics or blood vessels, leading to dissemination of viable organisms. Reactivation may occur at any time after the primary infection; commonly, it occurs years or decades later, in association with demonstrable waning of specific immune responses or in the presence of a high-risk condition associated with progressive TB. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Iatrogenic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, miliary TB may occur as a result of iatrogenic exposure. Disseminated TB has been reported after extracorporeal shock wave lithotripsy [
         <a href="#rid32">
          32,33
         </a>
         ], urethral catheterization [
         <a href="#rid34">
          34
         </a>
         ], and cardiac valve homograft placement [
         <a href="#rid35">
          35
         </a>
         ]. Tuberculosis also has been transmitted by solid organ transplantation [
         <a href="#rid36">
          36,37
         </a>
         ] or insertion of contaminated single-donor bone allograft matrix material containing viable cells and growth factors in spinal/bone surgery [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7623207">
         <span class="h2">
          Clinicopathologic patterns of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classically, the clinical and pathologic patterns of miliary TB have been divided into three groups: acute miliary TB, late generalized TB, and anergic (nonreactive) TB. These terms can be confusing because there is considerable overlap among the categories and the terminology is no longer frequently used. Acute miliary TB is primarily a clinical term; this entity can be seen in the immediate post-primary period or in immunocompromised children or adults. It is usually observed within the first two to six months following exposure, although progression may be more rapid in neonates and children under the age of one year [
         <a href="#rid39">
          39
         </a>
         ]. During one TB outbreak in an HIV housing facility in San Francisco, 11 of 30 HIV-infected residents (37 percent) who were exposed to an infectious pulmonary case of TB developed TB disease within 106 days; in one HIV-infected contact, TB was diagnosed within four weeks of exposure [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7623214">
         <span class="h3">
          Acute miliary tuberculosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute (generalized) miliary TB has a relatively rapid clinical course [
         <a href="#rid7">
          7,41
         </a>
         ]. Prior to the availability of effective chemotherapy for TB, most cases of acute miliary TB resulted from progressive primary disease. The pathologic hallmark of acute miliary TB is a caseating granulomatous reaction  (
         <a class="graphic graphic_picture graphicRef93762" href="/z/d/graphic/93762.html" rel="external">
          picture 2
         </a>
         ), with a smaller number of organisms than other forms of miliary disease [
         <a href="#rid7">
          7,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7623221">
         <span class="h3">
          Late generalized tuberculosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Late generalized TB refers to hematogenous spread that occurs after the primary or post-primary period. In one autopsy series of 100 patients with late generalized TB from 1937 to 1959, patients had relatively chronic, clinically nonspecific presentations [
         <a href="#rid42">
          42
         </a>
         ]. In this study, late generalized TB was frequently associated with chronic pulmonary TB. Since the availability of chemotherapy for TB, however, foci responsible for hematogenous spread are extrapulmonary in some cases and are thus more difficult to detect.
        </p>
        <p>
         A subset of late generalized TB is labeled cryptic miliary TB. This term refers to patients in whom the illness is even more indolent and who may demonstrate an attenuated histologic response [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7623228">
         <span class="h3">
          Anergic tuberculosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anergic TB is defined histologically by the absence of granulomata. In some cases, microabscesses containing large numbers of bacilli with a predominantly neutrophilic response are observed, although, in general, anergic TB is relatively difficult to establish based on histology [
         <a href="#rid44">
          44
         </a>
         ]. Tissue stains and cultures are generally used for diagnosis.
        </p>
        <p>
         Anergic (nonreactive) TB is a relatively uncommon form of miliary disease. The clinical spectrum ranges from overwhelming sepsis to nonspecific or typhoidal presentations. Most of the described cases are older patients with presumed reactivation TB. Granulomas in immunocompromised patients with TB may share similar characteristics [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Host and pathogen factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major determinants of TB dissemination include mycobacterial virulence factors and host immune defenses; these are not well defined [
         <a href="#rid46">
          46
         </a>
         ]. The high susceptibility of infants to miliary TB has led some investigators to speculate that the developing immune system may lack critical elements for initiating protective cellular immune responses to
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid21">
          21,22
         </a>
         ]. After initial infection, the development of specific cell-mediated (Type IV) immunity appears to be critical in limiting disseminated disease. Cytokines, including tumor necrosis factor-alpha, interleukin 12 and interferon-gamma, are essential for granuloma development and protective immunity to
         <em>
          M. tuberculosis
         </em>
         [
         <a href="#rid47">
          47,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8023.html" rel="external">
          "Tuberculosis: Natural history, microbiology, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8026.html" rel="external">
          "Immunology of tuberculosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8445244">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miliary tuberculosis (TB) refers to clinical disease that results from the hematogenous dissemination of
         <em>
          Mycobacterium tuberculosis;
         </em>
         it affects multiple organs and systems. Miliary TB can arise as a result of progressive primary infection or via reactivation of a previously contained (formerly termed latent) focus with subsequent spread. Miliary TB accounts for approximately 2 percent of incident cases in the United States, with increased representation among infants and young children and in individuals with concomitant immunosuppression. Extrapulmonary TB accounts for approximately 19 percent of cases. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk factors for the development of miliary TB include extremes of age and underlying medical conditions. Infants are highly susceptible to miliary TB, presumably due to their relatively immature immune systems. Older adults are also at increased risk for miliary TB due to relative waning of cellular immunity. Underlying medical conditions conferring increased risk for miliary TB include alcohol abuse, malignancy, HIV infection, immunosuppression (including chronic corticosteroid use and biologic agents such as tumor necrosis factor-alpha inhibitors), connective tissue disease, renal failure, diabetes, and pregnancy. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After establishing a primary focus of infection in the lung, tuberculous bacilli can disseminate via the lymphatics and hematogenously to the most vascular organs, such as the liver, spleen, bone marrow, and brain. These distant foci usually heal by granulomatous encapsulation over weeks to months. Failure of these foci to heal within the first six months after primary infection leads to progressive primary disease. Healed, viable foci can reactivate at any time after the primary infection; most commonly, reactivation occurs years or decades after primary infection, in association with waning of cellular immune responses or other risk factors. (See
         <a class="local">
          'Mechanisms of disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute (generalized) miliary TB has a relatively rapid clinical course. This entity can be seen in the immediate post-primary period
         <strong>
          or
         </strong>
         as a result of reactivation of a chronic focus; prior to the availability of anti-TB chemotherapy, most cases resulted from progressive primary disease. The pathologic hallmark of acute miliary TB is a caseating granulomatous reaction. (See
         <a class="local">
          'Acute miliary tuberculosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late generalized TB refers to hematogenous spread that occurs after the primary or post-primary period. Prior to the availability of effective TB chemotherapy, late generalized TB was frequently associated with chronic pulmonary TB. (See
         <a class="local">
          'Late generalized tuberculosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/en/ (Accessed on October 28, 2019).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2020. https://www.cdc.gov/tb/statistics/reports/2020/default.htm (Accessed on December 17, 2021).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2022. https://www.cdc.gov/tb/statistics/reports/2022/default.htm (Accessed on November 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005; 5:415.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Global tuberculosis report, 2022. https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1 (Accessed on November 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHAPMAN CB, WHORTON CM. Acute generalized miliary tuberculosis in adults. N Engl J Med 1946; 235:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore) 1984; 63:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieder HL, Kelly GD, Bloch AB, et al. Tuberculosis diagnosed at death in the United States. Chest 1991; 100:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1999. A 37-year-old man with fever and diffuse lymphadenopathy. N Engl J Med 1999; 340:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lado Lado FL, Barrio Gómez E, Carballo Arceo E, Cabarcos Ortíz de Barrón A. Clinical presentation of tuberculosis and the degree of immunodeficiency in patients with HIV infection. Scand J Infect Dis 1999; 31:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Reilly P, McDonnell T. The spectrum of mycobacterial disease in a Dublin teaching hospital. Ir Med J 1999; 92:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruijshaar ME, Abubakar I. Increase in extrapulmonary tuberculosis in England and Wales 1999-2006. Thorax 2009; 64:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snider DE Jr, Rieder HL, Combs D, et al. Tuberculosis in children. Pediatr Infect Dis J 1988; 7:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussey G, Chisholm T, Kibel M. Miliary tuberculosis in children: a review of 94 cases. Pediatr Infect Dis J 1991; 10:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith S, Jacobs RF, Wilson CB. Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity. J Pediatr 1997; 131:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev 2007; 8:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun MM, Coté TR, Rabkin CS. Trends in death with tuberculosis during the AIDS era. JAMA 1993; 269:2865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguado JM, Herrero JA, Gavaldá J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz P, Palomo J, Muñoz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakhuja V, Jha V, Varma PP, et al. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996; 61:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishizaki T, Yanaga K, Soejima Y, et al. Tuberculosis following liver transplantation: report of a case and review of the literature. Transpl Int 1996; 9:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagasawa M, Maeda H, Okawa H, Yata J. Pulmonary miliary tuberculosis and T-cell abnormalities in a severe combined immunodeficient patient reconstituted with haploidentical bone marrow transplantation. Int J Hematol 1994; 59:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munt PW. Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults. Medicine (Baltimore) 1972; 51:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med 1990; 89:291.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control. Extrapulmonary tuberculosis in the United States 1969-1973. DHEW publication no CDC 78-8260. Atlanta: Department of Health, Education and Welfare, 1978.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morano Amado LE, Amador Barciela L, Rodriguez Fernandez A, et al. Extracorporeal shock wave lithotripsy complicated with miliary tuberculosis. J Urol 1993; 149:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federmann M, Kley HK. Miliary tuberculosis after extracorporeal shock-wave lithotripsy. N Engl J Med 1990; 323:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yekanath H, Gross PA, Vitenson JH. Miliary tuberculosis following ureteral catheterization. Urology 1980; 16:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anyanwu CH, Nassau E, Yacoub M. Miliary tuberculosis following homograft valve replacement. Thorax 1976; 31:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qunibi WY, al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature. Q J Med 1990; 77:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz NG, Hernandez-Romieu AC, Annambhotla P, et al. Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report. Lancet Infect Dis 2022; 22:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PERRY TL. Natural history and pathogenesis of miliary and meningeal tuberculosis in children; analysis of 163 cases. Pediatrics 1950; 5:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stead WW. Pathogenesis of tuberculosis: clinical and epidemiologic perspective. Rev Infect Dis 1989; 11 Suppl 2:S366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavin RE, Walsh TJ, Pollack AD. Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore) 1980; 59:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proudfoot AT, Akhtar AJ, Douglas AC, Horne NW. Miliary tuberculosis in adults. Br Med J 1969; 2:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'BRIEN JR. Non-reactive tuberculosis. J Clin Pathol 1954; 7:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Noronha AL, Báfica A, Nogueira L, et al. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol Res Pract 2008; 204:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazurek J, Ignatowicz L, Kallenius G, et al. Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells. PLoS One 2012; 7:e42515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jouanguy E, Döffinger R, Dupuis S, et al. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11:346.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8029 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Latent Tuberculosis: Two Centuries of Confusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15978528" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Miliary tuberculosis: new insights into an old disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15978528" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Miliary tuberculosis: new insights into an old disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20996257" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute generalized miliary tuberculosis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6419006" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1889256" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Tuberculosis diagnosed at death in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1956280" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10026038" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1999. A 37-year-old man with fever and diffuse lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10528879" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical presentation of tuberculosis and the degree of immunodeficiency in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10394756" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The spectrum of mycobacterial disease in a Dublin teaching hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596589" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19854715" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850965" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Increase in extrapulmonary tuberculosis in England and Wales 1999-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1928942" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3285310" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tuberculosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4810628" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The prognosis of a positive tuberculin reaction in childhood and adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1749696" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Miliary tuberculosis in children: a review of 94 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9255187" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Immunobiology of childhood tuberculosis: a window on the ontogeny of cellular immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17574154" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical manifestations of tuberculosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497090" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Trends in death with tuberculosis during the AIDS era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9158022" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562750" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Tuberculosis in heart transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8600625" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The high incidence of tuberculosis among renal transplant recipients in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914240" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Tuberculosis following liver transplantation: report of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8086624" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pulmonary miliary tuberculosis and T-cell abnormalities in a severe combined immunodeficient patient reconstituted with haploidentical bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5013636" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Miliary tuberculosis in the chemotherapy era: with a clinical review in 69 American adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393033" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393033" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8501805" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Extracorporeal shock wave lithotripsy complicated with miliary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2215603" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Miliary tuberculosis after extracorporeal shock-wave lithotripsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7404920" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Miliary tuberculosis following ureteral catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/816028" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Miliary tuberculosis following homograft valve replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2267281" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7599848" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mycobacterium tuberculosis in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35934016" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15423956" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Natural history and pathogenesis of miliary and meningeal tuberculosis in children; analysis of 163 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1345800" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2711098" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pathogenesis of tuberculosis: clinical and epidemiologic perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7432152" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5780453" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Miliary tuberculosis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13192197" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Non-reactive tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18096327" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22880012" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9722917" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Mendelian susceptibility to mycobacterial infection in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10375558" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
